论文部分内容阅读
[目的]探讨国产培美曲塞单药或联合化疗方案治疗晚期复治NSCLC的疗效及毒副反应。[方法]选取25例经病理学或细胞学确诊,经一线或二线以上治疗失败的晚期复发性NSCLC患者,给予培美曲塞500mg/m2,d1,静脉滴注;其中10例联合顺铂70mg/m2,d1,静脉滴注。每3周重复。[结果]25例患者中无CR,PR4例(16%),SD10例(40%),PD11例(44%),总有效率为16%,临床获益率为56%。主要毒副反应为骨髓抑制,非血液学毒性反应较轻,耐受性良好。[结论]国产培美曲塞治疗晚期复治NSCLC临床获益率较好,且毒副反应可耐受。
[Objective] To investigate the efficacy and side effects of domestic pemetrexed monotherapy or combined chemotherapy in the treatment of advanced retreatment NSCLC. [Method] Twenty-five patients with advanced recurrent NSCLC whose pathology or cytology were diagnosed as having failed first-line or second-line treatment were given pemetrexed 500mg / m2, d1 for intravenous drip. Ten of them combined with 70mg of cisplatin / m2, d1, intravenous drip. Repeat every 3 weeks. [Results] None of the 25 patients had CR, PR 4 (16%), SD 10 (40%) and PD 11 (44%) with a total effective rate of 16% and a clinical benefit rate of 56%. The main toxicities were myelosuppression, mild non-hematologic toxicity and good tolerability. [Conclusion] The domestic pemetrexed treatment of advanced retreatment NSCLC clinical benefit rate is good, and the toxicity can be tolerated.